Phenytoin-induced bone loss and its prevention with alfacalcidol or calcitriol in growing rats

Calcified Tissue International

Volumn 69, Issue 2, 2001, Pages 109-116

  Onodera, K ^a,b   Takahashi, A ^b   Mayanagi, H ^b   Wakabayashi, H ^c   Kamei, J ^d   Shinoda, H ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^d HOSHI UNIVERSITY   (Japan)

Author keywords

Alfacalcidol; Bone mineral density; Osteocalcin; Osteopenia; Phenytoin

Indexed keywords

ALFACALCIDOL; CALCITRIOL; OSTEOCALCIN; PHENYTOIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CONTROLLED STUDY; MALE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOID; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; BONE DENSITY; BONE DISEASES, METABOLIC; CALCITRIOL; HYDROXYCHOLECALCIFEROLS; MALE; OSTEOCALCIN; OSTEOPOROSIS; PHENYTOIN; RATS; RATS, WISTAR;

EID: 0034885513     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-001-0020-7     Document Type: Article

References (41)

1. Altered calcium metabolism in epileptic children on anticonvulsants
2. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy
3. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children
4. 3 on the patients with antiepileptics for a long period
5. Osteopathien bei antiepileptischer dauerbehandlung
6. Osteopathien bei antiepileptischer langzeit-therapie (Vorläufige Mitteilung)
7. Osteomalacia with long-term anticonvulsant therapy in epilepsy
8. Disturbance of calcium metabolism by anticonvulsant drugs
9. Influence of phenobarbital and diphenylhydantoin on the healing of rickets in the rat
10. Effect of increasing doses of phenytoin on the plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations
11. Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial
12. Bone density in patients receiving long-term anticonvulsant therapy
13. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxyvitamin D
14. 3 concentrations in the rat
15. On the pathogenesis of anticonvulsant-drug-induced alterations of calcium metabolism
16. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy
17. Changes in bone turnover and deoxypyridinoline levels in epileptic patients
18. Agents affecting calcification and bone turnover: Calcium, phosphate, parathyroid hormone, vitamin D, calcitonin, and other compounds
19. Epilepsy and abnormal calcium metabolism in institutionalized mentally retarded patients
20. Low dose phenytoin is an osteogenic agent in the rat
21. Phenytoin and fluoride act in concert to stimulate bone formation and to increase bone volume in adult male rats
22. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-deriverd bone cells in vitro
23. Simple and rapid determination of bone mineral content in small experimental animals
24. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rays
25. An improved automated procedure for the determination of calcium in biological specimens
26. Improved procedure for histological identification of osteoid matrix in decalcified bone
27. 3
28. Biological activity of 25-hydroxyergocalciferol in rats
29. Fat-soluble vitamins XVII. The induction of growth-promoting and calcifying properties in a ration by exposure to ultra-violet light
30. Inhibition of intestinal calcium transport by diphenylhydantoin in rat duodenum
31. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat
32. The effects of phenytoin on calcium uptake in osteoblastic cells
33. Phenobarbital-induced alterations in vitamin D metabolism
34. Effect of phenobarbitone treatment on vitamin D metabolism in mammals
35. 3-activating cytochrome P-450-linked monooxygenase systems
36. Pharmacology and therapeutic use of vitamin D and its analogues
37. 3 concentrations in the rat
38. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria
39. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs
40. Drug-induced disorders of vitamin D and mineral metabolism
41. Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving anticonvulsant therapy. I. A survey of 288 patients